Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Closing the evidence gap in the use of emerging testing technologies in clinical practice.

Literature DB >> 19050197

Closing the evidence gap in the use of emerging testing technologies in clinical practice.

Kathryn A Phillips¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2008 PMID： 19050197 PMCID： PMC2910511 DOI： 10.1001/jama.2008.754

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

× No keyword cloud information.

7 in total

1. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.

Authors: Allison W Kurian; Rebecca Newton Thompson; Allison F Gaw; Sally Arai; Rafael Ortiz; Alan M Garber
Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544

2. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.

Authors: Nicola Lucio Liberato; Monia Marchetti; Giovanni Barosi
Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544

3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544

4. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.

Authors: Azadeh Stark; Gena Kucera; Mei Lu; Sarah Claud; Jennifer Griggs
Journal: Int J Qual Health Care Date: 2004-12 Impact factor: 2.038

5. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

Authors: Elena B Elkin; Milton C Weinstein; Eric P Winer; Karen M Kuntz; Stuart J Schnitt; Jane C Weeks
Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544

6. Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.

Authors: Lee N Newcomer
Journal: Health Aff (Millwood) Date: 2007-11-27 Impact factor: 6.301

Review 7. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

Authors: Muin J Khoury; Marta Gwinn; Paula W Yoon; Nicole Dowling; Cynthia A Moore; Linda Bradley
Journal: Genet Med Date: 2007-10 Impact factor: 8.822

7 in total

27 in total

1. A population approach to precision medicine.

Authors: Muin J Khoury; Marta L Gwinn; Russell E Glasgow; Barnett S Kramer
Journal: Am J Prev Med Date: 2012-06 Impact factor: 5.043

2. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors: Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal: J Oncol Pract Date: 2010-09 Impact factor: 3.840

Closing the evidence gap in the use of emerging testing technologies in clinical practice.

1. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.

2. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.

3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

4. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.

5. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

6. Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.

Review 7. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

1. A population approach to precision medicine.

2. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

3. Open innovation networks between academia and industry: an imperative for breakthrough therapies.

Review 4. Challenges of translating genetic tests into clinical and public health practice.

5. Genomic testing and therapies for breast cancer in clinical practice.

6. Health technology assessment and private payers' coverage of personalized medicine.

7. Do economic evaluations of targeted therapy provide support for decision makers?

8. Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample.

9. Translational research in cancer genetics: the road less traveled.

10. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.